Evaluation of a Mental Health Care App-Based Fatigue Management Program for Patients With Inflammatory Bowel Disease in Remission: Protocol for a Randomized Controlled Trial.

JMIR Res ProtocSep 28, 2026 (epub)
Clinical ResearchGastroenterology

Makoto Tanaka, Sayaka Wakai, Kayoko Sakagami et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial aims to evaluate a mobile cognitive behavioral intervention for fatigue management in patients with inflammatory bowel disease (IBD) in remission. The study involves adults diagnosed with Crohn disease or ulcerative colitis experiencing at least mild fatigue. The primary outcome is fatigue measured by the FACIT-F scale. Recruitment has concluded with 351 participants randomized.

Key findings

  • 351 participants were randomized after assessing 502 patients for eligibility.
  • 151 patients (30.0%) were excluded due to FACIT-F scores of 40 or higher.
  • The primary outcome is fatigue measured using the FACIT-F scale.

Why it matters

Fatigue significantly impacts the quality of life in patients with IBD, even during remission. Effective management strategies are essential for improving patient outcomes and overall well-being.

Source

PubMed · PMID 42803779

Published in JMIR Res Protoc. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Gastroenterology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.